Adamts13 treatment to enhance graft survival
AssigneeChildren's Medical Center Corporation
InventorsDenisa D. WAGNER, Siu Ling WONG
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method for treating and/or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.
Claims31
A method for treating or preventing graft rejection in a subject that received a graft, the method comprising administering to the subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13).
(canceled)
-11. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-28. (canceled)
-37. (canceled)
-41. (canceled)
A composition comprising ADAMTS13 and a carrier for use as a medicament for the treatment or prevention of graft rejection in a subject that received a graft.
-83. (canceled)
A method for determining the likelihood that a graft will be rejected by a subject, the method comprising:
- a. determining the level of NET and/or PAD4 in the graft, or a CSF or a blood sample obtained from the subject before the graft is transplanted,
- b. determining the level of NET and/or PAD4 in the graft, or the CSF or a blood sample obtained from the subject after the graft is transplanted,
- c. comparing the levels determined in steps (a) and (b), and
- d. determining that the subject is at risk for rejecting the graft if the level of NET and/or PAD4 in the graft, or the CSF or the blood of the subject has increased after the graft is transplanted as compared to a control.
-94. (canceled)
Dependencies are inferred from the claim text.